ArticleFrontiers in pharmacology2022
Cannabinoid CB
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- CB2R promotes T cell gut homing and exacerbates ileitis in a murine Crohn's model.Inflammatory bowel diseases · 2026Article
- The Endocannabinoid-Microbiota-Neuroimmune Super-System: A Unifying Feedback Architecture for Systems Resilience, Collapse Trajectories, and Precision Feedback Medicine.International journal of molecular sciences · 2025Review
- Neuroprotective effects of G9a inhibition and cannabinoid receptor activation in Alzheimer's disease through a pharmacological approach.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Exploring the impact of chronic intermittent EU-GMP certified Cannabis sativa L. therapy and its relevance in a rat model of aging.Journal of cannabis research · 2025Article
- Fatty-acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis.The FEBS journal · 2025Article
- Effect of neuroinflammation on the progression of Alzheimer's disease and its significant ramifications for novel anti-inflammatory treatments.IBRO neuroscience reports · 2025Review
- Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.Acta pharmacologica Sinica · 2025Review
- Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters.Frontiers in pharmacology · 2025Article
- Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications.International journal of molecular sciences · 2024Review
- Article
- A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research.International journal of molecular sciences · 2024Review
- 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.Neuropharmacology · 2024Article
- Cannabinoids' Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair.NeuroImmune pharmacology and therapeutics · 2023Article
- The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer's Disease.Journal of clinical medicine · 2023Review
- Imaging and Genetic Tools for the Investigation of the Endocannabinoid System in the CNS.International journal of molecular sciences · 2023Review
- Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells.International journal of molecular sciences · 2023Article
- Update on the controversial identity of cells expressing cnr2 gene in the nervous system.CNS neuroscience & therapeutics · 2023Review
- CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Samuel Ruiz de Martín EstebanFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
Irene Benito-CuestaFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
Itziar TerradillosDepartment of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
Ana M Martínez-RelimpioFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
M Andrea ArnanzFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
Gonzalo Ruiz-PérezFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
Claudia KornRoche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Catarina RaposoRoche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Roman C SarottLaboratorium Für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.
Matthias V WestphalLaboratorium Für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.
Izaskun ElezgaraiDepartment of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
Erick M CarreiraLaboratorium Für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.
Cecilia J HillardDepartment of Pharmacology and Toxicology, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, United States.
Uwe GretherRoche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Pedro GrandesDepartment of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
M Teresa GrandeFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
Julián RomeroFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain.
Universidad Francisco de Vitoria · ESAchucarro Basque Center for Neuroscience · ESETH Zurich · CHRoche (Switzerland) · CHMedical College of Wisconsin · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
The distribution and roles of the cannabinoid CB
Indexed as
Alzheimer’s diseaseamyloidcannabinoidsCB2 receptormicroglia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.